Journals / Akademik Gastroenteroloji Dergisi / 2019 / Cilt: 18 - Sayı: 2

The incidence and the demographic and clinical characteristics of patients with inflammatory bowel disease in our region

Bölgemizdeki inflamatuvar barsak hastalığı tanılı olguların insidansı, demografik ve klinik özellikleri

Pages
49–58
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The incidence rates for ulcerative colitis, Crohn’s disease, and indeterminate colitis were 3.67, 7.34, and 1.33 per 100 000 people, respectively

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Aims: This study was conducted to evaluate the clinical and demographic characteristics of patients diagnosed with inflammatory bowel disease who were followed up and treated in our tertiary care hospital for the past 1 year and to determine the annual incidence and prevalence according to the population.
📊
Key Findings & Data:Material and Methods: This retrospective study recorded and analyzed the clinical and demographic data of patients with inflammatory bowel disease who applied to Alanya Alaaddin Keykubat University Alanya Training and Research Hospital between July 2017 and July 2018.
💡
Conclusion & Impact:The incidence rates for ulcerative colitis, Crohn’s disease, and indeterminate colitis were 3.67, 7.34, and 1.33 per 100 000 people, respectively
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Background and Aims: This study was conducted to evaluate the clinical and demographic characteristics of patients diagnosed with inflammatory bowel disease who were followed up and treated in our tertiary care hospital for the past 1 year and to determine the annual incidence and prevalence according to the population. Material and Methods: This retrospective study recorded and analyzed the clinical and demographic data of patients with inflammatory bowel disease who applied to Alanya Alaaddin Keykubat University Alanya Training and Research Hospital between July 2017 and July 2018. Results: A total of 111 patients (53 patients with ulcerative colitis, 48 patients with Crohn’s disease, and 10 patients with indeterminate colitis) were included in this study. No significant difference was detected between the mean age and the gender distribution among patients with ulcerative colitis, Crohn’s disease, and indeterminate colitis. Ulcerative colitis (50.9%) and indeterminate colitis (70%) were more frequent among males, whereas Crohn’s disease (52.1%) was more frequent among females. Conclusions: In terms of the distribution according to age, ulcerative colitis showed the maximum prevalence of 60% in our region among patients in the age range of 40–49 years, whereas Crohn’s disease exhibited a bimodal peak, with prevalence rates of 53.8% in the 19–29-year age group and 57.1% in the age group of >60 years. The incidence rates for ulcerative colitis, Crohn’s disease, and indeterminate colitis were 3.67, 7.34, and 1.33 per 100 000 people, respectively

Özet

Giriş ve Amaç: Bu çalışmada üçüncü basamak hastanemizde son bir yıldır inflamatuvar barsak hastalıkları tanısı ile takip ve tedavi edilen hastaların klinik ve demografik özelliklerinin incelenmesi ve nüfusa göre yıllık insidans ve prevalansının belirlenmesi amaçlandı. Gereç ve Yöntem: Bu retrospektif çalışmada, Temmuz 2017 ile Temmuz 2018 arasında Alanya Alaaddin Keykubat Üniversitesi Alanya Eğitim ve Araştırma Hastanesi’ne başvuran inflamatuvar barsak hastalığı tanılı hastaların klinik ve demografik bilgileri kayıt edildi. Bulgular: Çalışmaya 111 hasta (53’ü ülseratif kolit, 48’i Crohn hastalığı, 10’u indetermine kolit) dahil edildi. Ülseratif kolit, Crohn hastalığı ve indetermine kolit hastalarında ortalama yaş ve cinsiyet dağılımları anlamlı farklılık göstermedi. Ülseratif kolit hastalığı %50.9 ile erkek cinsiyette daha sık görülürken, Crohn hastalığı %52.1 ile kadın cinsiyette ve indetermine kolit ise %70 ile erkek cinsiyette daha sık görülmekte idi. Sonuç: Yaşlara göre dağılımlara bakıldığında, bölgemizde ülseratif kolit 40-49 yaş aralığında %60 ile en sık görülürken, Crohn hastalığının ise 19-29 yaş aralığında %53.8 ve ≥60 yaşta %57.1 olmak üzere bimodal pik yaptığını izledik. Ülseratif kolit için insidans her 100 000’de 3.67 iken, Crohn hastalığı için her 100 000’de 7.34 olup, indetermine kolit için ise her 100 000’de 1.33 olarak tespit edilmiştir.

🔖

Cite This Article

ÇAKIR, Ö. Ö. (2019). The incidence and the demographic and clinical characteristics of patients with inflammatory bowel disease in our region. Akademik Gastroenteroloji Dergisi, Cilt: 18 - Sayı: 2, 49–58. https://ajindex.com/articles/142333

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Pierik M, Yang H, Barmada MM, et al. The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. Inflamm Bowel Dis. 2005;11:1-7
  2. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008;40:955-62
  3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17
  4. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-9
  5. Loftus EV Jr, Sandborn WJ. Epidemiology of infl ammatory bowel disease. Gastroenterol. Clin. North Am 2002;31:1-20
  6. M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol 2013;6:33-47
  7. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769-78
  8. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol 2015;50:942-51
  9. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6
  10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9
  11. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s Disease Activity Index. National Co-operative Crohn’s disease study. Gastroenterology 1976;70:439-44
  12. Tezel A, Dökmeci G, Eskiocak M, et al. Epidemiological features of ulcerative colitis in Trakya, Turkey. J Int Med Res 2003;31:141-8
  13. Tozun N, Atug O, Imeryuz N, et al; Members of the Turkish IBD Study Group. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol 2009;43:51-7
  14. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol 2017;15:857-63
  15. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14: